Join
Live feed
·
PRReleasevia Quantisnow
Protagonist Therapeutics Inc. logo

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

ByQuantisnow·Wall Street's wire, on your screen.
PTGX· Protagonist Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track PTGX (Protagonist Therapeutics Inc.) and more on Quantisnow.